Fig. 1: Rofecoxib harmful or naproxen beneficial? Time-to-event plot of confirmed serious cardiovascular adverse events in the VIGOR study. [Source: Cardiovascular safety review of rofecoxib by the US Food and Drug Administration using data from the study's sponsor, posted as a memorandum at www .fda .gov /ohrms/dockets/ac/01/briefing /3677 b2 _06 _cardio .pdf (accessed 2002 May 30).]